ArticleScientific reports2018
Ganetespib targets multiple levels of the receptor tyrosine kinase signaling cascade and preferentially inhibits ErbB2-overexpressing breast cancer cells.
Open access · goldAbstract read
In one paragraph
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 24 citations in OpenAlex.
- A phase 2 clinical trial of the heat shock protein 90 (HSP 90) inhibitor ganetespib in patients with refractory advanced esophagogastric cancer.Investigational new drugs · 2020Trial
- FGFR1 overexpression promotes resistance to PI3K inhibitor alpelisib in luminal breast cancer cells through receptor tyrosine kinase signaling-mediated activation of the estrogen receptor.Cancer drug resistance (Alhambra, Calif.) · 2025Article
- Overcoming cancer drug resistance through small-molecule targeting of HSP90 and HSP70.Cancer drug resistance (Alhambra, Calif.) · 2025Review
- Article
- Novel cancer treatment paradigm targeting hypoxia-induced factor in conjunction with current therapies to overcome resistance.Journal of experimental & clinical cancer research : CR · 2023Review
- A Coumarin-Imidazothiadiazole Derivative, SP11 Abrogates Tumor Growth by Targeting HSP90 and Its Client Proteins.Molecules (Basel, Switzerland) · 2023Article
- Exploring breast cancer exosomes for novel biomarkers of potential diagnostic and prognostic importance.3 Biotech · 2023Article
- The Chaperone System in Salivary Glands: Hsp90 Prospects for Differential Diagnosis and Treatment of Malignant Tumors.International journal of molecular sciences · 2022Article
- Ganetespib selectively sensitizes cancer cells for proximal and distal spread-out Bragg peak proton irradiation.Radiation oncology (London, England) · 2022Article
- Multiplexed Isobaric Quantitative Cross-Linking Reveals Drug-Induced Interactome Changes in Breast Cancer Cells.Analytical chemistry · 2022Article
- The HSP-RTK-Akt axis mediates acquired resistance to Ganetespib in HER2-positive breast cancer.Cell death & disease · 2021Article
- Article
- An insertion mutation of ERBB2 enhances breast cancer cell growth and confers resistance to lapatinib through AKT signaling pathway.Biology open · 2020Article
- Chaperoning STAT3/5 by Heat Shock Proteins: Interest of Their Targeting in Cancer Therapy.Cancers · 2019Review
- Traditional and Novel Mechanisms of Heat Shock Protein 90 (HSP90) Inhibition in Cancer Chemotherapy Including HSP90 Cleavage.Biomolecules & therapeutics · 2019Article
- Targeted blockade of HSP90 impairs DNA-damage response proteins and increases the sensitivity of ovarian carcinoma cells to PARP inhibition.Cancer biology & therapy · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Harry LeeJulius L. Chambers Biomedical/Biotechnology Research Institute, Department of Biological and Biomedical Sciences, North Carolina Central University, North Carolina Research Campus, Kannapolis, North Carolina, USA.
Nipun SainiJulius L. Chambers Biomedical/Biotechnology Research Institute, Department of Biological and Biomedical Sciences, North Carolina Central University, North Carolina Research Campus, Kannapolis, North Carolina, USA.
Erin W HowardJulius L. Chambers Biomedical/Biotechnology Research Institute, Department of Biological and Biomedical Sciences, North Carolina Central University, North Carolina Research Campus, Kannapolis, North Carolina, USA.
Amanda B ParrisJulius L. Chambers Biomedical/Biotechnology Research Institute, Department of Biological and Biomedical Sciences, North Carolina Central University, North Carolina Research Campus, Kannapolis, North Carolina, USA.
Zhikun MaJulius L. Chambers Biomedical/Biotechnology Research Institute, Department of Biological and Biomedical Sciences, North Carolina Central University, North Carolina Research Campus, Kannapolis, North Carolina, USA.
Qingxia ZhaoJulius L. Chambers Biomedical/Biotechnology Research Institute, Department of Biological and Biomedical Sciences, North Carolina Central University, North Carolina Research Campus, Kannapolis, North Carolina, USA.
Ming ZhaoJulius L. Chambers Biomedical/Biotechnology Research Institute, Department of Biological and Biomedical Sciences, North Carolina Central University, North Carolina Research Campus, Kannapolis, North Carolina, USA.
Bolin LiuDepartment of Pathology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Susan M EdgertonDepartment of Pathology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Ann D ThorDepartment of Pathology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Xiaohe YangJulius L. Chambers Biomedical/Biotechnology Research Institute, Department of Biological and Biomedical Sciences, North Carolina Central University, North Carolina Research Campus, Kannapolis, North Carolina, USA. xyang@nccu.edu.
North Carolina Central University · USUniversity of Colorado Anschutz Medical Campus · US
Funding
Understanding Perceptions of HIV Risk, PrEP, and PrEP use among African American Women Attending an HBCUU54MD012392 · NIMHD · NORTH CAROLINA CENTRAL UNIVERSITY · PI MICHELER Ricardo RICHARDSON · 2017 to 2026
$38.1MRC3 Ethanol-Cannabinoid Interaction in the Regulation of NeurogenesisU54AA019765 · NIAAA · NORTH CAROLINA CENTRAL UNIVERSITY · PI COLE, GREGORY JAY · 2010 to 2019
$8.7MMechanisms of in utero exposure to bisphenol A induced mammary tumor riskR21ES025337 · NIEHS · NORTH CAROLINA CENTRAL UNIVERSITY · PI YANG, XIAOHE · 2015 to 2016
$410kNIAAA NIH HHS U54 AA019765NIEHS NIH HHS R21 ES025337NIMHD NIH HHS U54 MD012392
Abstract
Although ErbB2-targeted therapeutics have significantly improved ErbB2
Indexed as
AnimalsAntineoplastic AgentsApoptosisBreast NeoplasmsCell ProliferationCell SurvivalDrug SynergismErb-b2 Receptor Tyrosine KinasesFemaleG2 Phase Cell Cycle CheckpointsHalf-LifeHSP90 Heat-Shock ProteinsHumansLapatinibMCF-7 CellsMiceAntineoplastic AgentsERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesHSP90 Heat-Shock ProteinsLapatinibReceptor Protein-Tyrosine KinasesSTA 9090Triazoles
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.